Prognostic relevance of the intrinsic growth deceleration of the first passage xenografts of human renal cell carcinomas

Bassukas, Ioannis D.; Hofmockel, G.; Tsatalpas, Panagiotis; Eberle, Victor; Maurer‐Schultze, B.

doi:10.1002/(sici)1097-0142(19961115)78:10<2170::aid-cncr19>3.0.co;2-w

Cited by 6 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mathematical modelling of tumour growth can provide not only key insights into tumour biology but also tools for, e.g., optimization of screening programs, cancer patient prognosis [1], scheduling of chemotherapy [2], and assessment of tumour spread [3,4]. For example, Norton et al showed that, considering the mathematical growth model of breast cancer tumours, patients must be treated with condensed-dose chemotherapy, and a clinical trial showed the significant benefit for the patients treated with the new method compared with the patients treated with the standard treatment [5,6].…”

Section: Introductionmentioning

confidence: 99%

Analysis of inter-patient variations in tumour growth rate

Mehrara

Forssell-Aronsson

2014

Theor Biol Med Model

View full text Add to dashboard Cite

PurposeInter-patient variations in tumour growth rate are usually interpreted as biological heterogeneity among patients due to, e.g., genetic variability. However, these variations might be a result of non-exponential, e.g. the Gompertzian, tumour growth kinetics. The aim was to study if the natural tumour growth deceleration, i.e. non-exponential growth, is a dominant factor in such variations.Materials and methodsThe correlation between specific growth rate (SGR) and the logarithm of tumour volume, Ln(V), was calculated for tumours in patients with meningioma, hepatocellular carcinoma, pancreatic carcinoma, primary lung cancer, post-chemotherapy regrowth of non-small cell lung cancer (NSCLC), and in nude mice transplanted with human midgut carcinoid GOT1, a tumour group which is biologically more homogeneous than patient groups.ResultsThe correlation between SGR and Ln(V) was statistically significant for meningioma, post-chemotherapy regrowth of NSCLC, and the mouse model, but not for any other patient groups or subgroups, based on differentiation and clinical stage.ConclusionThis method can be used to evaluate the homogeneity of tumour growth kinetics among patients. Homogeneity of post-chemotherapy regrowth pattern of NSCLC suggests that, in contrast to untreated tumours, the remaining resistant cells or stem cells (if exist) might have similar biological characteristics among these patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Analysis of inter-patient variations in tumour growth rate

Mehrara

Forssell-Aronsson

2014

Theor Biol Med Model

View full text Add to dashboard Cite

show abstract

“…Studying natural tumour growth is valuable for understanding tumour biology, optimising screening programs, prognostication [1], optimal scheduling of chemotherapy [2], and assessing tumour spread (number and size distribution of metastases, including micro-metastases) [3,4]. Mathematical models such as the exponential and the Gompertzian growth models are usually used to describe tumour growth.…”

Section: Introductionmentioning

confidence: 99%

A new method to estimate parameters of the growth model for metastatic tumours

Mehrara

Forssell-Aronsson

Johanson

et al. 2013

Theor Biol Med Model

View full text Add to dashboard Cite

PurposeKnowledge of natural tumour growth is valuable for understanding tumour biology, optimising screening programs, prognostication, optimal scheduling of chemotherapy, and assessing tumour spread. However, mathematical modelling in individuals is hampered by the limited data available. We aimed to develop a method to estimate parameters of the growth model and formation rate of metastases in individual patients.Materials and methodsData from one patient with liver metastases from a primary ileum carcinoid and one patient with lung metastases from a primary renal cell carcinoma were used to demonstrate this new method. Metastatic growth models were estimated by direct curve fitting, as well as with the new proposed method based on the relationship between tumour growth rate and tumour volume. The new model was derived from the Gompertzian growth model by eliminating the time factor (age of metastases), which made it possible to perform the calculations using data from all metastases in each patient. Finally, the formation time of each metastasis and, consecutively, the formation rate of metastases in each patient were estimated.ResultsWith limited measurements in clinical studies, fitting different growth curves was insufficient to estimate true tumour growth, even if patients were followed for several years. Growth of liver metastases was well described with a general growth model for all metastases. However, the lung metastases from renal cell carcinoma were better described by heterogeneous exponential growth with various growth rates.ConclusionAnalysis of the regression of tumour growth rate with the logarithm of tumour volume can be used to estimate parameters of the tumour growth model and metastasis formation rates, and therefore the number and size distribution of metastases in individuals.

show abstract

Untitled

Possati

Campioni

Sola³

et al. 1999

Clinical and Experimental Metastasis

View full text Add to dashboard Cite

The antiangiogenic, antitumoural and antimetastatic effects of two novel sulphonic derivatives of distamycin A, PNU145156E and PNU153429, were studied in a Kaposi's sarcoma-like tumour model obtained by injecting nude mice with cells releasing extracellular HIV-Tat protein, derived from a tumour which developed in a BK virus/tat transgenic mouse. Both PNU145156E and PNU153429 were administered intraperitoneally every fourth day for three weeks at doses of 100 or 50 mg/kg of body weight respectively, starting one day after injecting the tumour cells. Both drugs delayed tumour growth in nude mice, preventing neovascularization induced by the Tat protein. PNU153429 also significantly reduced the number and size of spontaneous tumour metastases. Both effects on tumour growth and metastases were augmented by treating simultaneously nude mice with 7.5 mg/kg of body weight of minocycline given per os daily for four weeks starting four days after injecting the tumour cells. Neither acute nor chronic toxic side-effects were observed during the life span of treated nude mice. Due to their antiangiogenic and anti-Tat effects, these drugs are promising for the treatment of Kaposi's sarcoma in AIDS patients.

show abstract

Prognostic relevance of the intrinsic growth deceleration of the first passage xenografts of human renal cell carcinomas

Cited by 6 publications

References 3 publications

Analysis of inter-patient variations in tumour growth rate

Analysis of inter-patient variations in tumour growth rate

A new method to estimate parameters of the growth model for metastatic tumours

Untitled

Contact Info

Product

Resources

About